Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
-
Publication number: 20100119478Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE) are described.Type: ApplicationFiled: August 20, 2009Publication date: May 13, 2010Applicant: PROBIODRUG AGInventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Kathrin Gans, Stephen Schilling, Sonja Kampfer
-
Publication number: 20100111970Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: ApplicationFiled: November 16, 2009Publication date: May 6, 2010Inventors: Jaume Pons, Arnon Rosenthal
-
Patent number: 7691977Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.Type: GrantFiled: October 19, 2006Date of Patent: April 6, 2010Assignee: Genentech, Inc.Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
-
Patent number: 7691603Abstract: The invention includes methods and compositions for forming peptide conjugates intracellularly having a covalent linkage between a modifying group and a glycosylated or non-glycosylated peptide. The modifying group is conjugated to the peptide via a glycosyl linking group interposed between and covalently linked to both the peptide and the modifying group.Type: GrantFiled: April 9, 2004Date of Patent: April 6, 2010Assignee: Novo Nordisk A/SInventor: Shawn DeFrees
-
Patent number: 7691378Abstract: The present invention relates to methods for treating carcinomas or adenocarcinomas using at least one anti-TNF antibody.Type: GrantFiled: September 30, 2004Date of Patent: April 6, 2010Assignee: Centocor, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Patent number: 7691379Abstract: The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients.Type: GrantFiled: April 12, 2005Date of Patent: April 6, 2010Assignee: Medimmune, LLCInventor: Christian B. Allan
-
Patent number: 7678373Abstract: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.Type: GrantFiled: February 9, 2007Date of Patent: March 16, 2010Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Dorothy French
-
Publication number: 20100061986Abstract: The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.Type: ApplicationFiled: January 23, 2008Publication date: March 11, 2010Applicants: Shinshu University, Chugai Seiyaku Kabushiki KaishaInventors: Masafumi Takahashi, Atsushi Izawa
-
Patent number: 7674461Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: GrantFiled: July 27, 2007Date of Patent: March 9, 2010Assignee: Zymogenetics, Inc.Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Patent number: 7667002Abstract: Early developing stage-specific liver proteins and the genes coding for them that have been isolated and sequenced are provided, and these genes and proteins can be utilized to diagnose and/or treat a wide variety of liver disorders and other ailments. Since the early developing liver proteins of the invention arise during embryogenesis when the liver and other organs are in transition from an undifferentiated state to a differentiated one, these proteins are involved in tissue differentiation and thus can be utilized in methods of diagnosing and treating a variety of liver diseases and other disorders including those relating to oncogenesis and tissue repair. Antibodies recognizing early developing liver proteins and peptides are also provided.Type: GrantFiled: April 10, 2007Date of Patent: February 23, 2010Inventor: Lopa Mishra
-
Patent number: 7662379Abstract: The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, the methods and compositions provided herein relate to humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.Type: GrantFiled: January 12, 2007Date of Patent: February 16, 2010Assignee: Schering CorporationInventor: Leonard G. Presta
-
Patent number: 7662382Abstract: The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and ?1?1 integrin.Type: GrantFiled: February 8, 2008Date of Patent: February 16, 2010Assignee: Boys Town National Research HospitalInventor: Dominic Cosgrove
-
Patent number: 7659378Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: June 1, 2007Date of Patent: February 9, 2010Assignee: AVEO Pharmaceuticals, Inc.Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
-
Patent number: 7658920Abstract: Polypeptide growth factor ZVEGF3, methods of making it, polynucleotides encoding it, antibodies that bind to it, and methods of using them are disclosed. The polypeptide comprises an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptide are also disclosed. The polypeptide, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents. The antibodies may be used to inhibit cell growth.Type: GrantFiled: October 24, 2006Date of Patent: February 9, 2010Assignee: ZymoGenetics, Inc.Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker
-
Patent number: 7659375Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.Type: GrantFiled: June 25, 2007Date of Patent: February 9, 2010Assignee: Immunex CorporationInventors: John E Sims, Dirk E Smith
-
Patent number: 7655763Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: GrantFiled: July 13, 2007Date of Patent: February 2, 2010Assignees: Wyeth, MedImmune LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Patent number: 7645450Abstract: Humanized antibodies specifically binding to hTNF-? are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the original mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a hTNF-?-related disease such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis.Type: GrantFiled: December 29, 2005Date of Patent: January 12, 2010Assignee: Yuhan CorporationInventors: Tae Hyoung Yoo, Moo Young Song, Chang Seok Kim, Sang Koo Park, Kang In Na, Byung Kyu Lee, Heui Il Kang
-
Publication number: 20090324604Abstract: M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: January 6, 2005Publication date: December 31, 2009Applicants: CHIRON CORPORATION, XOMA Technology Ltd.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory M. Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Arnold Horwitz, Maria Calderon-Cacia
-
Publication number: 20090324605Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.Type: ApplicationFiled: August 31, 2009Publication date: December 31, 2009Applicant: Medarex, Inc.Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David Passmore
-
Publication number: 20090317921Abstract: The present invention provides an improved antibody specific for the inhibin/activin beta-B subunit polypeptide. The antibody is highly specific for the beta-B subunit in a sample, and does not require processing of the sample with heat or oxidizing agents. Thus, discovery of the new antibody provides for simpler, more accurate immunoassays for a wider range of sample types.Type: ApplicationFiled: June 11, 2009Publication date: December 24, 2009Applicant: OXFORD BROOKES UNIVERSITYInventors: Nigel Patrick Groome, Helen Ludlow
-
Patent number: 7635767Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.Type: GrantFiled: January 26, 2009Date of Patent: December 22, 2009Assignee: ZymoGenetics, Inc.Inventors: Mark W. Rixon, Jane A. Gross
-
Patent number: 7635760Abstract: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.Type: GrantFiled: October 5, 2006Date of Patent: December 22, 2009Assignee: Eli Lilly and CompanyInventors: Bomie Han, Andrew Korytko, Pamela Jean Mitchell, Linda O'Bryan, Rong Wang, Rosamund Carol Smith
-
Patent number: 7632926Abstract: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.Type: GrantFiled: March 29, 2007Date of Patent: December 15, 2009Assignee: Galaxy Biotech, LLCInventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Maximiliano Vasquez
-
Patent number: 7632501Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.Type: GrantFiled: July 11, 2008Date of Patent: December 15, 2009Assignee: Biogen IDEC MA Inc.Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
-
Patent number: 7626002Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: September 18, 2006Date of Patent: December 1, 2009Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 7622559Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: June 27, 2007Date of Patent: November 24, 2009Assignee: Genmab A/SInventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jørgen Petersen
-
Patent number: 7622555Abstract: This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease. The invention also relates to the identification of the extracellular domain of INSP052.Type: GrantFiled: November 12, 2003Date of Patent: November 24, 2009Assignee: Ares Trading S.A.Inventors: Andrew Robert Davids, Richard Joseph Fagan, Christopher Benjamin Phelps, Christine Power, Yolande Chvatchko, Ursula Boschert
-
Patent number: 7615213Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: GrantFiled: June 9, 2005Date of Patent: November 10, 2009Assignee: WyethInventors: Marion T. Kasaian, Lioudmila Tchistiakova, Geertruida M. Veldman, Kimberly Ann Marquette, Xiang-Yang Tan, Debra D. Donaldson, Laura Long Lin, Tania Shane, Amy Sze Pui Tam, Eric Feyfant, Nancy L. Wood, Lori J. Fitz, Angela M. Widom, Kevin D. Parris, Samuel J. Goldman, Jose W. Saldanha
-
Publication number: 20090274647Abstract: The present invention is related to pharmaceutical compositions based on vaccines and monoclonal antibodies that neutralize the Interleukin-2, which are useful in the treatment of tumors. Particularly the present invention is related to therapeutic formulations able to increase the immunogenicity of the IL-2 conjugated to the carrier protein P64k from the neisseria meningitidis in montanide ISA 51 adjuvant for the induction of IL-2 neutralizing autoantibodies and the effective methods for the treatment of tumors, including breast cancer and melanoma. Furthermore, the present invention is related to therapeutic combination of the IL-2 based vaccine with other cancer vaccines based on specific tumor antigens or tumor growth factors, as well as chemotherapeutics agents or radiotherapy of standard use for cancer treatment.Type: ApplicationFiled: November 16, 2005Publication date: November 5, 2009Inventors: José Enrique Montero Casimiro, Liván Bladimir Alonso Sarduy, Rolando Pérez Rodríguez, Agustín Bienvenido Lage Dávila
-
Patent number: 7612182Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: August 1, 2007Date of Patent: November 3, 2009Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
-
Publication number: 20090269336Abstract: The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.Type: ApplicationFiled: April 29, 2008Publication date: October 29, 2009Applicants: Taiwan Liposome Co. Ltd, TLC Biopharmaceuticals, Inc.Inventors: Keelung Hong, Luke S.S. Guo, Yun-Long Tseng, Hsiu-Li Song, Po-Chun Chang, Sheue-Fang Shih
-
Patent number: 7608690Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: December 6, 2004Date of Patent: October 27, 2009Assignee: Schering CorporationInventor: J. Fernando Bazan
-
Patent number: 7608694Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1?, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.Type: GrantFiled: February 6, 2004Date of Patent: October 27, 2009Assignee: UCB Pharma S.A.Inventors: Alastair David Griffiths Lawson, Andrew George Popplewell
-
Patent number: 7605236Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: GrantFiled: November 4, 2005Date of Patent: October 20, 2009Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Steven C. Barash, Gil H. Choi, Tristan Vaughan, David Hilbert
-
Patent number: 7601815Abstract: Novel CC chemokines from human, reagents related thereto including purified proteins, specific antibodies and nucleic acids encoding these chemokines are provided. Also provided are methods of making and using said reagents and diagnostic kits.Type: GrantFiled: May 16, 2006Date of Patent: October 13, 2009Assignee: Schering CorporationInventors: Alain P. Vicari, Janine M. Morales, Joseph A. Hedrick, Albert Zlotnik
-
Publication number: 20090252741Abstract: Although results from preclinical studies in animal models have proven the concept for use of anti-CTLA-4 antibodies in cancer immunotherapy, two major obstacles have hindered their successful application for human cancer therapy. First, the lack of in vitro correlates of the anti-tumor effect of the antibodies makes it difficult to screen for the most efficacious antibody by in vitro analysis. Second, significant autoimmune side-effects have been observed In a recent clinical trial. In order to address these two issues, we have generated human CTLA-4 gene knock-in mice and used them to compare a panel of anti-human CTLA-4 antibodies for their ability to induce tumor rejection and autoimmunity. Surprisingly, while all antibodies induced protection against cancer and demonstrated some autoimmune side effects, the antibody that induced the strongest protection also induced the least autoimmune side effects. These results demonstrate that autoimmune disease does not quantitatively correlate with cancer immunity.Type: ApplicationFiled: September 7, 2005Publication date: October 8, 2009Applicant: OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Yang Liu, Pan Zheng, Kenneth May, JR., Ken Lute
-
Publication number: 20090252723Abstract: The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.Type: ApplicationFiled: October 28, 2005Publication date: October 8, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD>Inventors: Etsuo Ohshima, Hirokazu Kawasaki, Naoya Kimoto, Akihiko Watanabe
-
Patent number: 7597886Abstract: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.Type: GrantFiled: July 6, 2001Date of Patent: October 6, 2009Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen, Jun Zhang
-
Patent number: 7588761Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: September 21, 2005Date of Patent: September 15, 2009Assignee: Abbott Biotechnology Ltd.Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 7585500Abstract: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.Type: GrantFiled: November 16, 2005Date of Patent: September 8, 2009Assignee: Amgen Inc.Inventors: Ian Foltz, Raffaella Faggioni, Giorgio Senaldi, Kathy Manchulenko, Jaspal S. Kang, Palaniswami Rathanaswami, Kiran Ahluwalia, Orit Foord, Scott Klakamp
-
Patent number: 7585504Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: GrantFiled: October 21, 2005Date of Patent: September 8, 2009Assignee: MedImmune, LLCInventors: Herren Wu, Christian B. Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
-
Publication number: 20090220521Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: December 30, 2008Publication date: September 3, 2009Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Patent number: 7582297Abstract: The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.Type: GrantFiled: April 12, 2004Date of Patent: September 1, 2009Assignee: MedImmune, LLCInventor: Jennifer Lynne Reed
-
Patent number: 7575893Abstract: The present invention provides methods for producing humanized antibodies and increasing the yield of antibodies and/or antigen binding fragments when produced in cell culture. In one aspect of the invention, at least one framework region amino acid residue of the variable domain is substituted by a corresponding amino acid from a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequence of the variable domain. In another aspect, an amino acid is placed at a position proximal to a cys residue that participates in an intrachain variable domain disulfide bond that corresponds to an amino acid found at that position in a variable domain consensus sequence subgroup that has the most sequence identity with the HVR1 and/or HVR2 amino acid sequenc of the variable domain.Type: GrantFiled: January 23, 2004Date of Patent: August 18, 2009Assignee: Genentech, Inc.Inventor: Laura Simmons
-
Patent number: 7572441Abstract: A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance with homeopathic technology. In order to obtain antibodies, human or heterologous interferon alpha, beta, or gamma, including recombinant interferon, is used; a mixture of various, mostly centimal, homeopathic dilutions being employed. A method of treating a pathologic syndrome, whose formation is affected by interferon, consists in the use of activated forms of antibodies to interferon alpha, beta, or gamma in low or ultra-low doses obtained by multiple consecutive dilutions and exposure to external factors.Type: GrantFiled: August 2, 2002Date of Patent: August 11, 2009Inventors: Oleg Iliich Epshtein, Goldberg Evgeny Danilovich, Alexandr Mikhailovich Dygay
-
Patent number: 7572766Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.Type: GrantFiled: June 15, 2005Date of Patent: August 11, 2009Inventors: Wayne F. Beyer, Jr., Robin Hyde-DeRuyscher, Paul T. Hamilton, Ray Edward Benson
-
Patent number: 7560112Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: April 28, 2006Date of Patent: July 14, 2009Assignees: Applied Molecular Evolution, Inc., Centocor Ortho Biotech Inc.Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
-
Patent number: 7560533Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: September 18, 2002Date of Patent: July 14, 2009Assignee: Schering CorporationInventors: Karin Franz-Bacon, Daniel M. Gorman, Terrill K. McClanahan
-
Publication number: 20090175881Abstract: Engineered antibodies to human IL-17A are provided, as well as uses thereof.Type: ApplicationFiled: August 9, 2007Publication date: July 9, 2009Inventors: Leonard G. Presta, Edward P. Bowman
-
Publication number: 20090162355Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: June 13, 2008Publication date: June 25, 2009Inventors: Daniela Gast, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Kruger, Silke Wolterink, Sandra Luttgau, Ulrich Mobius, Yi Li